Taken together, these data show that sitagliptin (i) increased CD8+ T cell/Treg ratios and (ii) reduced the expression of immunosuppressive cytokines, thereby altering the entire circulating immune landscape during the early dissemination stages of ovarian cancer. Here, CD8A is linked to ovarian carcinoma.